EP Patent

EP0121901A1 — pH independent controlled releasable tablets

Assigned to Boehringer Ingelheim Pharmaceuticals Inc · Expires 1984-10-17 · 42y expired

What this patent protects

Novel pH independent, controlled release oral tablets comprising an effective amount of an intimate mixture of dipyridamole or an acid addition salt thereof, at least 18 acid equivalents of at least one non-toxic, pharmaceutical acid or acid substance per mole of dipyridamole and…

USPTO Abstract

Novel pH independent, controlled release oral tablets comprising an effective amount of an intimate mixture of dipyridamole or an acid addition salt thereof, at least 18 acid equivalents of at least one non-toxic, pharmaceutical acid or acid substance per mole of dipyridamole and a sufficient amount of a disintegration agent to allow at least 90% dissolution of dipyridamole in the gastrointestinal pH range of 1 to 7.

Drugs covered by this patent

Patent Metadata

Patent number
EP0121901A1
Jurisdiction
EP
Classification
—
Expires
1984-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.